基于国家专利的中药复方调治病毒性心肌炎用药规律研究
|
摘要
目的分析调治病毒性心肌炎中药复方专利的用药配伍规律,为中药新药研发、专利保护提供参考。方法计算机检索国家知识产权局专利公布公告网站(http://epub.sipo.gov.cn)建库至2018年7月31日调治病毒性心肌炎的中药复方专利数据。采用中医传承辅助平台(V2.5)进行频次统计、关联规则、复杂网络、熵聚类等分析。结果纳入中药复方专利179项,涉及药物712味,最常见的主治证候为气阴两虚证(52次,29.05%);最常用的药物为麦冬(75次,41.90%)、五味子(75次,41.90%),最常用的对药为麦冬-五味子(49次,27.37%),常用的角药有麦冬-丹参-五味子(30次,16.76%)、麦冬-党参-五味子(25次,13.97%)等;高置信度关联规则有"炙甘草-当归→五味子""麦冬-黄连→五味子""黄连-党参→五味子"等;核心药物为麦冬、五味子、丹参等;新处方有"板蓝根-薄荷-荆芥-黄芩-磁石""半夏-白术-炙甘草-茯神-远志-当归""丹参-黄连-连翘-党参-柴胡"等。结论临床研发调治病毒性心肌炎中药可针对其常见主治证候,活用益气、养阴、活血、祛瘀、行气之品,灵活处方以提高临床疗效。
Objective To analyze the medication and compatibility rules of compound TCM patents for treatment of viral myocarditis; To provide references for research and development of new TCM and patent protection.Methods All compound TCM patents related to the treatment of viral myocarditis were extracted from the national patent database(http://epub.sipo.gov.cn) from the establishment of the database to 31 st, July 2018. TCM Inheritance Support System(V2.5) was used to conduct frequency statistics, association rules, complex network, and entropy clustering. Results Totally 179 compound TCM patents were included, involving 712 kinds of Chinese materia medica, and the most common syndrome was deficiency of both qi and yin syndrome(52 times, accounting for29.05%). The most common Chinese materia medica was Ophiopogonis Radix(75 times, accounting for 41.90%) and Schisandrae Chinensis Fructus(75 times, accounting for 41.90%). The most common medical combination was Ophiopogonis Radix-Schisandrae Chinensis Fructus(49 times, accounting for 27.37%). The most common triple combinations were Ophiopogonis Radix-Salviae Miltiorrhizae Radix et Rhizoma-Ophiopogonis Radix(30 times,accounting for 16.76%) and Ophiopogonis Radix-Codonopsis Radix-Ophiopogonis Radix(25 times, accounting for13.97%). Confidence-based association rules were "Glycyrrhizae Radix et Rhizoma Praeparata cum Melle-Angelicae Sinensis Radix→Schisandrae Chinensis Fructus", "Ophiopogonis Radix-Coptidis Rhizoma→Schisandrae Chinensis Fructus", "Coptidis Rhizoma-Codonopsis Radix→Schisandrae Chinensis Fructus". The core medicines were Ophiopogonis Radix, Schisandrae Chinensis Fructus, and Salviae Miltiorrhizae Radix et Rhizoma. The new prescriptions were "Isatidis Radix-Menthae Haplocalycis Herba-Schizonepetae Herba-Astragali Radix-Magnetitum", "Pinelliae Rhizoma-Atractylodis Macrocephalae Rhizoma-Glycyrrhizae Radix et Rhizoma Praeparata cum Melle-Poria-Polygalae Radix-Angelicae Sinensis Radix", and "Salviae Miltiorrhizae Radix et Rhizoma-Coptidis Rhizoma-Forsythiae Fructus-Codonopsis Radix-Bupleuri Radix". Conclusion Clinical research and development of new TCM for the treatment of viral myocarditis should give priority to main syndromes,flexibly using medicines for tonifying qi, nourishing yin, activating blood circulation, dissipating blood stasis, and motivating qi to promote clinical efficacy.
Objective To analyze the medication and compatibility rules of compound TCM patents for treatment of viral myocarditis; To provide references for research and development of new TCM and patent protection.Methods All compound TCM patents related to the treatment of viral myocarditis were extracted from the national patent database(http://epub.sipo.gov.cn) from the establishment of the database to 31 st, July 2018. TCM Inheritance Support System(V2.5) was used to conduct frequency statistics, association rules, complex network, and entropy clustering. Results Totally 179 compound TCM patents were included, involving 712 kinds of Chinese materia medica, and the most common syndrome was deficiency of both qi and yin syndrome(52 times, accounting for29.05%). The most common Chinese materia medica was Ophiopogonis Radix(75 times, accounting for 41.90%) and Schisandrae Chinensis Fructus(75 times, accounting for 41.90%). The most common medical combination was Ophiopogonis Radix-Schisandrae Chinensis Fructus(49 times, accounting for 27.37%). The most common triple combinations were Ophiopogonis Radix-Salviae Miltiorrhizae Radix et Rhizoma-Ophiopogonis Radix(30 times,accounting for 16.76%) and Ophiopogonis Radix-Codonopsis Radix-Ophiopogonis Radix(25 times, accounting for13.97%). Confidence-based association rules were "Glycyrrhizae Radix et Rhizoma Praeparata cum Melle-Angelicae Sinensis Radix→Schisandrae Chinensis Fructus", "Ophiopogonis Radix-Coptidis Rhizoma→Schisandrae Chinensis Fructus", "Coptidis Rhizoma-Codonopsis Radix→Schisandrae Chinensis Fructus". The core medicines were Ophiopogonis Radix, Schisandrae Chinensis Fructus, and Salviae Miltiorrhizae Radix et Rhizoma. The new prescriptions were "Isatidis Radix-Menthae Haplocalycis Herba-Schizonepetae Herba-Astragali Radix-Magnetitum", "Pinelliae Rhizoma-Atractylodis Macrocephalae Rhizoma-Glycyrrhizae Radix et Rhizoma Praeparata cum Melle-Poria-Polygalae Radix-Angelicae Sinensis Radix", and "Salviae Miltiorrhizae Radix et Rhizoma-Coptidis Rhizoma-Forsythiae Fructus-Codonopsis Radix-Bupleuri Radix". Conclusion Clinical research and development of new TCM for the treatment of viral myocarditis should give priority to main syndromes,flexibly using medicines for tonifying qi, nourishing yin, activating blood circulation, dissipating blood stasis, and motivating qi to promote clinical efficacy.
引文
[1]张军平.我国病毒性心肌炎流行病学分析[C]//中国中西医结合学会心血管专业委员会,中华中医药学会介入心脏病专家委员会,黄河心血管病防治论坛组委会.第二届全国中西医结合心血管病中青年论坛暨第二届黄河心血管病防治论坛资料汇编.中国中西医结合学会,2011:5.
[2]POLLACK A,KONTOROVICH A R,FUSTER V,et al.Viral myocarditisdiagnosis,treatment options,and current controversies[J].Nat Rev Cardiol,2015,12(11):670-680.
[3]郭建波,何庆勇,王阶,等.基于国家专利的中药复方治疗心力衰竭用药规律研究[J].中国中医药信息杂志,2018,25(8):98-101.
[4]国家药典委员会.中华人民共和国药典:一部[M].北京:中国医药科技出版社,2015.
[5]南京中医药大学.中药大辞典[M].上海:上海科学技术出版社,2006.
[6]国家技术监督局.中医临床诊疗术语·证候部分:GB/T16751.2-1997[S].北京:国家标准出版社,1997:1-41.
[7]中医药学名词审定委员会.中医药学名词[M].北京:科学出版社,2004:56-124.
[8]张旻昱,吴宏伟,许利平,等.五味子及其活性成分调治心脑血管疾病药理作用的研究进展[J].中国中药杂志,2018,43(8):1536-1546.
[9]彭婉,马骁,王建,等.麦冬化学成分及药理作用研究进展[J].中草药,2018,49(2):477-488.
[10]蔺瑞,段佳林,牟菲,等.丹参主要活性成分体内代谢途径及产物研究进展[J].中国新药杂志,2017,26(19):2271-2277.
[2]POLLACK A,KONTOROVICH A R,FUSTER V,et al.Viral myocarditisdiagnosis,treatment options,and current controversies[J].Nat Rev Cardiol,2015,12(11):670-680.
[3]郭建波,何庆勇,王阶,等.基于国家专利的中药复方治疗心力衰竭用药规律研究[J].中国中医药信息杂志,2018,25(8):98-101.
[4]国家药典委员会.中华人民共和国药典:一部[M].北京:中国医药科技出版社,2015.
[5]南京中医药大学.中药大辞典[M].上海:上海科学技术出版社,2006.
[6]国家技术监督局.中医临床诊疗术语·证候部分:GB/T16751.2-1997[S].北京:国家标准出版社,1997:1-41.
[7]中医药学名词审定委员会.中医药学名词[M].北京:科学出版社,2004:56-124.
[8]张旻昱,吴宏伟,许利平,等.五味子及其活性成分调治心脑血管疾病药理作用的研究进展[J].中国中药杂志,2018,43(8):1536-1546.
[9]彭婉,马骁,王建,等.麦冬化学成分及药理作用研究进展[J].中草药,2018,49(2):477-488.
[10]蔺瑞,段佳林,牟菲,等.丹参主要活性成分体内代谢途径及产物研究进展[J].中国新药杂志,2017,26(19):2271-2277.